Scott Runyon

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Search Publications

Filter

Filter by Year

Search Results

Discovery of 1,3-disubstituted pyrazole peripheral cannabinoid receptor partial agonists

Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding

Structure-activity relationship development efforts towards peripherally selective analogs of the cannabinoid receptor partial agonist BAY 59-3074

Synthesis and characterization of an orally bioavailable small molecule agonist of the apelin receptor

Preclinical efficacy and selectivity of vaccines targeting fentanyl, alfentanil, sufentanil, and acetylfentanyl in rats

Efficacy and selectivity of monovalent and bivalent vaccination strategies to protect against exposure to carfentanil, fentanyl, and their mixtures in rats

Identification of a novel neuropeptide S receptor antagonist scaffold based on the SHA-68 core

Pyrazole agonist of the apelin receptor improves symptoms of metabolic syndrome in mice

Aplnr knockout mice display sex-specific changes in conditioned fear

Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity

Synthesis of [3 H] and [14 C]Genipin

Identification of potent pyrazole based APELIN receptor (APJ) agonists

Functionalized 6-(piperidin-1-yl)-8,9-diphenyl purines as inverse agonists of the CB1 receptor - SAR efforts towards selectivity and peripheralization

Functionalized 6-(piperidin-1-yl)-8,9-diphenyl purines as peripherally restricted inverse agonists of the CB1 receptor

Formulation and characterization of conjugate vaccines to reduce opioid use disorders suitable for pharmaceutical manufacturing and clinical evaluation

Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins

Potent and selective tetrahydroisoquinoline kappa opioid receptor antagonists of lead compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic)

Potent and selective tetrahydroisoquinoline kappa opioid receptor antagonists of lead compound (3r)-7-hydroxy-n-[(1s)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (pdtic)

Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists

Anti-Mullerian hormone as a biomarker for acute testicular degeneration caused by toxic insults to stallion testes